Replimune Group

Replimune Group Working Capital

The Working Capital of Replimune Group (REPL) as of Nov 10, 2026 is 219.27 M USD. In the previous year, Working Capital was 385.96 M USD — a change of -43.19% (lower).

Working Capital

219.27 MUSD

YoY

-43.19%

Last updated:

Working Capital of Replimune Group is 2026 219.27 M USD. Working Capital of Replimune Group was 2025 385.96 M USD. It decreases by -43.19% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Replimune Group Stock analysis

What does Replimune Group do? Replimune Group Inc is an American biotechnology company based in Woburn, Massachusetts. The company focuses on the development of therapeutics for cancer treatments through the application of oncolytic viruses. Replimune Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Replimune Group stock

Working Capital of Replimune Group is 219.27 M USD in 2026.

Working Capital of Replimune Group changed from 385.96 M USD to 219.27 M USD, representing a -43.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Replimune Group since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Replimune Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Replimune Group

All Key Metrics — Replimune Group